The KCTD20 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional analysis of the KCTD20 gene in a human non-small cell lung adenocarcinoma background. This product provides a genetically disrupted KCTD20 loss-of-function model, generated using CRISPR/Cas9 technology to introduce targeted gene disruption in the NCI-H1975 cell line. The resulting polyclonal pool offers a heterogeneous population of cells with KCTD20 gene ablation, avoiding biases from single-cell cloning and enabling robust assessment of gene function in a biologically relevant cancer model.
The NCI-H1975 host cell line is a well-characterized lung adenocarcinoma epithelial cell line derived from a non-small cell lung carcinoma. It harbors activating EGFR mutations (L858R and T790M) and a TP53 mutation, making it a clinically relevant model for studying EGFR-driven NSCLC and mechanisms of acquired resistance to tyrosine kinase inhibitors. This genetic background provides a disease-relevant context for investigating how KCTD20 may influence oncogenic signaling, protein homeostasis, and cancer cell behavior.
KCTD20 is a member of the potassium channel tetramerization domain-containing family and is predicted to function as a substrate adaptor for the Cullin-3 (CUL3)-RING E3 ubiquitin ligase complex. It interacts with CUL3 and RBX1, facilitating the transfer of ubiquitin onto specific substrate proteins, thereby targeting them for proteasomal degradation. By recruiting substrates to the CUL3-RING ligase, KCTD20 regulates ubiquitin-dependent proteolysis and protein stability. Although its direct substrates are currently unidentified, loss of KCTD20 is expected to stabilize its target proteins, potentially altering downstream signaling networks.
Within the NCI-H1975 lung adenocarcinoma cells, KCTD20 knockout may perturb proteostasis and modify cancer cell phenotypes such as proliferation, migration, apoptosis, or sensitivity to EGFR-targeted therapies. The combination of EGFR and TP53 mutations in this line creates a unique environment to study how ubiquitin-mediated degradation influences oncogenic processes. This model enables investigation into the functional significance of KCTD20-mediated ubiquitination and may uncover novel dependencies or therapeutic targets in non-small cell lung cancer.
This polyclonal knockout product supports a range of research applications, including western blotting to assess global ubiquitination profiles, cycloheximide chase assays to measure protein half-life, and co-immunoprecipitation to validate KCTD20-CUL3 interactions. Cell-based functional assays such as viability, migration, and invasion studies can reveal the impact of KCTD20 loss on tumorigenic properties. Transcriptomic analysis by RT-qPCR may identify transcriptional changes downstream of KCTD20 disruption. The model is also suitable for screening small molecules or genetic modifiers that interact with the ubiquitin-proteasome system in NSCLC. For additional information, please contact Ascent Research.
